Select a community
HIV
Find out more about the PatientsLikeMe
HIV Community
Home > Community Treatment Reports > Amitriptyline Treatment Report
What is Amitriptyline?

Amitriptyline is a tricyclic antidepressant approved for the treatment of depression. Off label amitripyline is used for certain chronic and neuropathic (nerve) pain and for prevention of migraine headaches.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken
# of patients Efficacy
Major
Moderate
Slight
None
Can’t tell
# of patients evaluated by
Other 3 0
Nerve pain 2 0
Depression 2 2
Migraine Headaches 1 0
General health 1 0
Insomnia 1 0

See all 11 patients currently taking Amitriptyline

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
1 50%
None
1 50%

Most commonly reported side effects

dry mouth
1 100%
  • Mild
  • Moderate
  • Severe

Dosages

  1 other daily 10 mg daily 25 mg daily 50 mg daily 100 mg daily 150 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 4 Number of Patients: 4 2 Number of Patients: 2 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Amitriptyline (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice
1 100% Doctor's advice: 100%

See all 1 patient who’ve stopped taking Amitriptyline

Currently Taking Amitriptyline

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0

Stopped Taking Amitriptyline

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
2 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
2 100%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
2 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on March 20, 2010.